{"id":"W4313252357","doi":"10.1016/j.xkme.2022.100596","title":"Polycystic Kidney Disease Drug Development: A Conference Report","year":2022,"lang":"en","type":"article","venue":"Kidney Medicine","topic":"Genetic and Kidney Cyst Diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; PKD Australia; European Medicines Agency; Universitätsklinikum Köln; Otsuka Pharmaceutical; Government of South Australia; Heinrich Hertz Stiftung; European Paediatric Neurology Society; University of Colorado; University of Kansas; University of Chicago; Tufts Medical Center; Manitoba Beekeepers' Association; Children's Hospital of Philadelphia; American Society of Nephrology; University of Toronto; Case Western Reserve University; U.S. Department of Health and Human Services; Yale University; PKD Foundation; Tufts University School of Medicine; Universitair Ziekenhuis Gent; Mayo Clinic","keywords":"Autosomal dominant polycystic kidney disease; Tolvaptan; Polycystic kidney disease; Medicine; PKD1; Drug development; Disease; Intensive care medicine; Kidney disease; Internal medicine; Lenvatinib; Bioinformatics; Drug; Pharmacology; Biology; Heart failure; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003726982,0.000256868,0.0002398103,0.00008740889,0.0003580338,0.00001215835,0.000385558,0.00003860372,0.002176699],"category_scores_gemma":[0.001940808,0.0002351732,0.00007577745,0.0001766616,0.0001884861,0.000003056032,0.00037087,0.0001448656,0.00002980457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003864156,"about_ca_system_score_gemma":0.002587545,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003597068,"about_ca_topic_score_gemma":0.000001802818,"domain_scores_codex":[0.9979305,0.0001226097,0.0004227931,0.0006096977,0.0005207706,0.0003936408],"domain_scores_gemma":[0.9970696,0.00001201732,0.000153224,0.0006450176,0.00009625535,0.002023892],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005193703,0.0002078145,0.005525604,0.0001023742,0.0001133485,0.0005393768,0.0003695711,0.00001267025,0.07687941,0.00007419391,0.9150814,0.0005748277],"study_design_scores_gemma":[0.001525795,0.0001514225,0.006525274,0.00006556878,0.0001021079,0.0001902254,0.0003251451,0.00004648114,0.00589203,0.0001960128,0.9846226,0.0003573253],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.852052,0.009381656,0.007219147,0.07153991,0.006361817,0.002388522,0.001279002,0.0003660902,0.04941184],"genre_scores_gemma":[0.9592928,0.00004834253,0.0003669728,0.01356342,0.0004759393,0.0002107324,0.003681179,0.00003932573,0.02232132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1072408,"threshold_uncertainty_score":0.9987354,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01219201171451289,"score_gpt":0.250738858133489,"score_spread":0.2385468464189761,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}